$Cassava Sciences Warrants(SAVAW.US)$New Recent January MDPI Scientific Article with Bullish statement about Simufilam. ’Another important aspect of dementia research is the development of new therapeutic approaches aimed at curing the disease or alleviating its symptoms. Hoau-Yan Wang and colleagues [10] investigated the molecular mechanisms of simufilam, a novel oral drug candidate in phase 3 clinical trials for Alzheimer’s dementia. The authors showed that simufilam reduces Aβ42 binding to...